Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
企業コードPBMWW
会社名Psyence Biomedical Ltd
上場日Dec 10, 2021
最高経営責任者「CEO」Dr. Neil Maresky
従業員数- -
証券種類Company Warrant
決算期末- -
本社所在地121 Richmond Street West Penthouse
都市TORONTO
証券取引所NASDAQ Capital Market Consolidated
国Canada
郵便番号M5H 2K1
電話番号17744604171
ウェブサイト
企業コードPBMWW
上場日Dec 10, 2021
最高経営責任者「CEO」Dr. Neil Maresky
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし